MedPath

A comparison of peginterferon alfa-2a plus ribavirin and peginterferon alfa-2b plus ribavirin for. postmenopausal women. with chronic hepatitis type C : An open-label randomized controlled trial.

Phase 2
Conditions
Chronic hepatitis C
Registration Number
JPRN-UMIN000001604
Lead Sponsor
Hiroshima liver study group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients receiving shosaiko-to 2)Autoimmune hepatitis 3)History of hypersensitivity to PEG-IFN alpha-2a and PEG-IFN alpha-2b 4)History of hypersensitivity to biological products such as vaccine 5)Decompenstated liver cirrhosis 6)HCC, malignat tumor 7)With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 8)Pregnant or lactating women and women who may be pregnant 9)Judged by investigator not to be appropriate for inclusion in this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath